Krystal Biotech, Inc. Common Stock vs. Moderna, Inc. Common Stock
KRYS
Krystal Biotech, Inc. Common Stock
$337.02 -1.84%
VS MRNAModerna, Inc. Common Stock
$133.32 -23.55%
Krystal Biotech, Inc. Common Stock (KRYS) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| KRYS | MRNA | |
|---|---|---|
| Market Cap | $10.16 billion | $69.62 billion |
| Revenue (TTM) | $440.48 million | $2.23 billion |
| Net Income (TTM) | $241.47 million | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| KRYS | MRNA | |
|---|---|---|
| P/E Ratio | 42.23 | — |
| Price / Book | 7.48 | 10.30 |
| Price / Sales | 23.07 | 31.25 |
KRYS leads on 2 of 2 valuation factors.
Profitability
| KRYS | MRNA | |
|---|---|---|
| Net Margin | 54.82% | -141.43% |
| Return on Equity | 17.77% | -46.61% |
KRYS leads on 2 of 2 profitability factors.
Risk & Sentiment
| KRYS | MRNA | |
|---|---|---|
| Short Interest | 0.11% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: KRYS overview, KRYS financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.